关键词: HCC , 免疫治疗 , 肝移植 , 免疫检查点抑制剂

Abstract:

Objective To explore the association between immune therapy and the risk of rejection after liver transplantation in patients with hepatocellular carcinoma （HCC）. Methods A retrospective analysis was conducted on 11 HCC patients who received immune therapy before transplantation at Beijing Friendship Hospital from 2019 to 2025， and 70 cases reported in the literature were included. The incidence of rejection and influencing factors were analyzed. Results The rejection rate in our center's cohort was 9.1% （1/11）， which was lower than that in theneoadjuvant therapy cohort （25.0%）and the post-transplantation cohort （30.8%）in the literature. The rejection rate was significantly reduced when the interval between the last dose of immune therapy and transplantation was more than two halflives. The expression of programmed death ligand 1（PD-L1）in the graft may be related to the risk of rejection and could serve as a potential biomarker for predicting rejection. Conclusion It is recommended to wait at least 8 weeks （two halflives）after immune therapy before liver transplantation. The expression levels of programmed death receptor 1（PD-1）/PDL1 in the graft tissue can be used as potential biomarkers， but further research is needed to explore the mechanism and safe time intervas. 

Key words:

Hepatocellular carcinoma； , Immunotherapy； , Liver transplantation； , Immune checkpoint inhibitors